EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Treatment and Prognosis of Newly Diagnosed Advanced-Stage Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Real-World Study across Two Decades

Yu-Ce Wei, Fei Qi, Bo Chen, Chang-Gong Zhang, Hui Fang, Di Zhang, Shu-Nan Qi, Yue Chai, Ye-Xiong Li, Mei Dong

Chemotherapy · 2024

DOI: 10.1159/000535128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemotherapy, 2024. Verfasst von Yu-Ce Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Lymphoma, Extranodal NK-T-Cell, Antineoplastic Combined Chemotherapy Protocols, Asparaginase, Neoplasm Staging. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although there is now a consensus on asparaginase-based chemotherapy regimens in the treatment of advanced-stage extranodal natural killer/T-cell lymphomas (ENKTCLs), patient survival in the real-world setting is still not optimistic according to previous literature reports, and the optimal chemotherapeutic regimens and integration of different therapeutic methods under the concept of combined-modality treatment still need to be further explored and verified.

Methods

Newly diagnosed stage Ⅲ/Ⅳ ENKTCL patients from Chinese National Cancer Center in the last two decades were retrospectively collected and analyzed. Overall survival (OS) and progression-free survival (PFS) were determined as primary endpoints. Log-rank tests and Cox proportional hazard models were performed to test for survival differences between subgroups and examine the univariable and multivariable associations.

Results

The study included 83 newly diagnosed stage Ⅲ/Ⅳ ENKTCL patients and reported a median OS of 26.07 months and an estimated 5-year OS of 41.3% with a median follow-up of 82.13 months. First-line asparaginase-based regimens compared to non-asparaginase-based regimens significantly prolonged PFS (p = 0.007; HR = 0.48, p = 0.020) and showed a tendency to improve OS (p = 0.064; HR = 0.74, p = 0.359). Gemcitabine-based regimens also exhibited a trend toward improved PFS (p = 0.048; HR = 0.59, p = 0.164) and OS (p = 0.008; HR = 0.67, p = 0.282) compared to non-gemcitabine-based ones. The asparaginase and gemcitabine combinations yielded a 5-year OS of 55.0% and led to significantly superior PFS (p = 0.020; HR = 0.40, p = 0.022) and slightly better OS (p = 0.054; HR = 0.79, p = 0.495) compared to the remaining regimens. First-line combined-modality treatment integrating chemotherapy and radiotherapy improved PFS (p = 0.051) and OS (p = 0.036) compared to chemotherapy alone. Four autologous hematopoietic stem cell transplantation recipients reached a median OS of 58.34 months.

Conclusion

Asparaginase and gemcitabine alone brought a favorable impact on PFS and OS; and the asparaginase and gemcitabine combination chemotherapy yielded the optimal efficacy, response duration, and survival outcomes. Combined-modality treatment including potent chemotherapy supplemented by radiotherapy and/or consolidative transplantation could improve prognosis in newly diagnosed advanced-stage ENKTCLs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Extranodal NK-T-CellAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseNeoplasm StagingHumansMaleFemaleMiddle AgedRetrospective StudiesAdultPrognosisAgedYoung AdultProportional Hazards ModelsAdolescentGemcitabineProgression-Free SurvivalCombined Modality Therapy

Stichwörter der Autor:innen

Advanced-stage extranodal NKChemotherapyPrognosisRadiotherapyT-cell lymphomaTreatment

Substanzen

AsparaginaseGemcitabine

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, weiyc037820@126.…
  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Zitieren

APA

Wei, Y. C., Qi, F., Chen, B., Zhang, C. G., Fang, H., Zhang, D., Qi, S. N., Chai, Y., Li, Y. X., & Dong, M. (2024). Treatment and Prognosis of Newly Diagnosed Advanced-Stage Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Real-World Study across Two Decades. Chemotherapy. https://doi.org/10.1159/000535128

Vancouver

Wei YC, Qi F, Chen B, Zhang CG, Fang H, Zhang D, et al. Treatment and Prognosis of Newly Diagnosed Advanced-Stage Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Real-World Study across Two Decades. Chemotherapy. 2024. doi:10.1159/000535128

BibTeX
@article{Wei2024,
  author = {Wei, Yu-Ce and Qi, Fei and Chen, Bo and Zhang, Chang-Gong and Fang, Hui and Zhang, Di and Qi, Shu-Nan and Chai, Yue and Li, Ye-Xiong and Dong, Mei},
  title = {Treatment and Prognosis of Newly Diagnosed Advanced-Stage Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Real-World Study across Two Decades},
  journal = {Chemotherapy},
  year = {2024},
  doi = {10.1159/000535128}
}
Kostenlos starten →